Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

40.81USD
10:56am EST
Change (% chg)

$-1.23 (-2.93%)
Prev Close
$42.04
Open
$41.93
Day's High
$41.93
Day's Low
$40.76
Volume
93,032
Avg. Vol
366,455
52-wk High
$55.15
52-wk Low
$31.25

NBIX.OQ

Chart for NBIX.OQ

About

Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc.... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $3,652.07
Shares Outstanding(Mil.): 86.87
Dividend: --
Yield (%): --

Financials

  NBIX.OQ Industry Sector
P/E (TTM): -- 45.12 30.76
EPS (TTM): -1.45 -- --
ROI: -29.76 -1.32 14.89
ROE: -31.49 -0.98 16.30

BRIEF-Neurocrine announces completion of phase II clinical study of VMAT2 Inhibitor Ingrezza

* Neurocrine announces completion of phase II clinical study of VMAT2 inhibitor Ingrezza (valbenazine) in adults with tourette syndrome

Jan 17 2017

BRIEF-Neurocrine Biosciences announces FDA advisory committee meeting to review Ingrezza NDA

* Neurocrine announces FDA advisory committee meeting to review Ingrezza (valbenazine) new drug application for the treatment of tardive dyskinesia

Nov 29 2016

BRIEF-Jana Partners cuts sole share stake in Alphabet, takes sole share stake in Mondelez International

* Jana Partners LLC takes sole share stake of 111,127 shares in Sage Therapeutics Inc

Nov 14 2016

BRIEF-Neurocrine Biosciences posts Q3 loss per share $0.43

* Q3 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S

Nov 02 2016

BRIEF-Neurocrine announces FDA conditional acceptance of Ingrezza

* Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza for VMAT2 inhibitor valbenazine

Aug 31 2016

BRIEF-Neurocrine submits NDA for Valbenazine

* Submits new drug application for Valbenazine for treatment of tardive dyskinesia

Aug 29 2016

BRIEF-Neurocrine Biosciences Q2 loss per share $0.46

* Q2 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

Aug 03 2016

BRIEF-Neurocrine announces start of phase ii study of tourette

* Neurocrine announces initiation of a long-term phase ii clinical study of vmat2 inhibitor valbenazine in tourette syndrome Source text for Eikon: Further company coverage:

Jul 28 2016

Earnings vs. Estimates